Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen – Eli Lilly

Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or single dose vial, starting at $299 per month for the 2.5 mg dose.

“Zepbound is the #1 prescribed injectable obesity‑management medication, helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds as seen in SURMOUNT-5,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines.”

The demand for Zepbound highlights its strong efficacy profile. In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. In the SURMOUNT-5 open-label study, people who took Zepbound on average lost 50 lbs (20.2% weight loss) compared to people who took injectable Wegovy and on average lost 33 lbs (13.7% weight loss).

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.

Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses are 10 mg or 15 mg for OSA.

About SURMOUNT-1
Throughout the 72 week clinical trial, people who took Zepbound sustained weight loss—whether taking the 5 mg, 10 mg, or 15 mg dose along with diet and exercise. In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.

About SURMOUNT-5
SURMOUNT-5 was a 72-week, multi-center, randomized, open-label, Phase IIIb trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with injectable Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Data collected in a less rigorous study so findings are less certain. Factors beyond studied medications may have contributed to weight loss. In the 72-week study participants on Zepbound Maximum Tolerated Dose (MTD) (10 mg or 15 mg, the max dose a participant could tolerate) experienced on average a 20.2% (50 Ibs) weight loss compared to an average of 13.7% (33 Ibs) weight loss for participants on Wegovy MTD (1.7 mg or 2.4 mg, the max dose a participant could tolerate). Average starting weights were 248.4 lbs for Zepbound MTD and 250 lbs for Wegovy MTD. Wegovy is a registered trademark of Novo Nordisk A/S.